




Global Pandemic Prevention and Biodefense Center

Metropolitan Washington Council of Governments

April 14, 2021


Our region contains unmatched assets and capabilities for global pandemic prevention



The Region:

- Extensive ecosystem of government, industry, academia, and non-profits
- Home to more than 70 federal labs, 800 life sciences companies, the FDA, NIH/NIAID, ASPR/BARDA, DARPA, and other critical national biodefense assets
- Leading pharma and biotech industry companies and biohealth incubators
- World renowned academia and research institutions (e.g. University System of Maryland, Johns Hopkins, George Mason, George Washington)
- Global center of non-profits and philanthropy

The Global Pandemic Prevention and Biodefense Center accelerates pandemic preparedness by coordinating and delivering innovative solutions across sectors to rapidly contain disease outbreaks



60
MINUTES



The Center will deliver AHEAD100 (Advanced Human Epidemic Antibody Defenses), an innovative program to develop and stockpile human monoclonal antibody (mAbs) for the top 100 pandemic-potential pathogens




Monoclonal antibodies have emerged as most promising amongst therapeutics solutions due to their usability across all populations.



mAbs prevent and treat infection, providing an **effective strategy to contain outbreaks**, an essential component of rapid response.



Major philanthropic funders and governments have expressed interest in funding antibody research.



More than 100 mAbs have been developed since their inception in 1985 for various indications. They represent the largest market in pharma.



CDMV has established partnerships with leading stakeholders engaged in mAbs research and discovery.

Steering Committee

Steering Committee Facilitator
Stu Solomon, Co-Lead

Rich Bendis, Co-Lead
Dr. James Crowe, AHEAD100

Non-Profits		Academia	Government		Industry	
CEPI	WHO <i>(ex-officio)</i>	University System of Maryland	NIH / NIAID / VRC <i>(ex-officio)</i>	State of Maryland	Moderna	DLA Piper
Biotechnology Innovation Organization (BIO)	Bipartisan Commission on Biodefense	Vanderbilt University Medical Center	NIH / NIAID / MID <i>(ex-officio)</i>	Montgomery County	AstraZeneca	BeatTheReaper
S&R Foundation	Bill & Melinda Gates Foundation	Consortium of Universities of Washington Metro Area	NIH / NCATS <i>(ex-officio)</i>	HHS / ASPR / BARDA <i>TBD</i>	Regeneron	Twist Bioscience
White House Physician Emeritus	Former ASD for Nuclear, Chemical, and Biological Defense	International Academic Institution / Europe <i>Future</i>	USAMRDC / USAMRIID <i>Future</i>	JPEO-CBRND <i>Future</i>	Emergent BioSolutions	Berkeley Lights
Virginia Bio	Maryland Tech Council	International Academic Institution / Asia <i>Future</i>	Walter Reed Army Institute of Research	eMed <i>(Prior AMA Chair)</i>	GSK	Kaiser Permanente
Montgomery County Economic Dev. Corp.	US Pharmacopeia	Connected DMV	BioHealth Innovation	Pinkston	Becton Dickinson	Life Science Venture Capitalist

We can create the necessary countermeasures to contain pandemic-potential pathogens within 100 days of outbreak

